%0 Journal Article
%A Jahn, Nikolaus
%A Jahn, Ekaterina
%A Saadati, Maral
%A Bullinger, Lars
%A Larson, Richard A
%A Ottone, Tiziana
%A Amadori, Sergio
%A Prior, Thomas W
%A Brandwein, Joseph M
%A Appelbaum, Frederick R
%A Medeiros, Bruno C
%A Tallman, Martin S
%A Ehninger, Gerhard
%A Heuser, Michael
%A Ganser, Arnold
%A Pallaud, Celine
%A Gathmann, Insa
%A Krzykalla, Julia
%A Benner, Axel
%A Bloomfield, Clara D
%A Thiede, Christian
%A Stone, Richard M
%A Döhner, Hartmut
%A Döhner, Konstanze
%T Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.
%J Leukemia
%V 36
%N 9
%@ 0887-6924
%C London
%I Springer Nature
%M DKFZ-2022-01731
%P 2218-2227
%D 2022
%Z 2022 Sep;36(9):2218-2227
%X The aim of this study was to characterize the mutational landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the randomized CALGB 10603/RATIFY trial evaluating intensive chemotherapy plus the multi-kinase inhibitor midostaurin versus placebo. We performed sequencing of 262 genes in 475 patients: mutations occurring concurrently with the FLT3-mutation were most frequent in NPM1 (61
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:35922444
%R 10.1038/s41375-022-01650-w
%U https://inrepo02.dkfz.de/record/181024